{"analyses":[{"ciLowerLimit":"0.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.90","groupDescription":"Stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0063","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.21","upperLimit":"7.69","value":"5.55"},{"groupId":"OG001","lowerLimit":"6.80","upperLimit":"9.86","value":"8.28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"336"}],"units":"Participants"}],"description":"Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \\>/= 5 millimeters (mm).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - Global"},{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"MEDIAN","populationDescription":"Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.","reportingStatus":"POSTED","timeFrame":"Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)","title":"TTP-IRF Per HCC mRECIST in the Global Population","type":"SECONDARY","unitOfMeasure":"months"}